Acute kidney injury: Cell cycle arrest biomarkers win race for AKI diagnosis

Nature Reviews Nephrology

Volumn 10, Issue 12, 2014, Pages 683-685

  Endre, Zoltán H ^a   Pickering, John W ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; GELATINASE A;

ACUTE KIDNEY FAILURE; CELL CYCLE ARREST; CONSENSUS; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIALYSIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; PATIENT MONITORING; PREDICTIVE VALUE; PROTEIN URINE LEVEL; REVIEW; RISK ASSESSMENT; SEPSIS; UROLOGICAL DIAGNOSTIC DEVICE; ACUTE KIDNEY INJURY; CELL CYCLE CHECKPOINT; EARLY DIAGNOSIS; FEMALE; FLUOROIMMUNOASSAY; FOOD AND DRUG ADMINISTRATION; HOSPITAL INFORMATION SYSTEM; MALE; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; UNITED STATES; URINE;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CELL CYCLE CHECKPOINTS; EARLY DIAGNOSIS; FEMALE; FLUOROIMMUNOASSAY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MATRIX METALLOPROTEINASE 2; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84911493830     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.198     Document Type: Review

References (10)

1. FDA news release. FDA allows marketing of the first test to assess risk of developing acute kidney injury [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412910.htm (2014).
2. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. Section 2: AKI Definition. Kidney Int. Suppl. 2, 7-24 (2012).
3. Hoste, E. A. et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol. Dial. Transpl. http://dx.doi.org/10.1093/ndt/gfu292.
4. Bihorac, A. et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am. J. Respir. Crit. Care Med. 189, 932-939 (2014).
5. Kashani, K. et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013).
6. McCullough, P. A. et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib. Nephrol. 182, 5-12 (2013).
7. Nickolas, T. L. et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59, 246-255 (2012).
8. Pickering, J. W. & Endre, Z. H. Linking injury to outcome in acute kidney injury: a matter of sensitivity. PLoS ONE 8, e62691 (2013).
9. Endre, Z. H. et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int. 79, 1119-1130 (2011).
10. Endre, Z. H. & Pickering, J. W. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Kidney Int. 84, 644-647 (2013).